Thanks for posting Hartland. This sounds like the ZEN-3694 w/ enzalutamide combo trial Phase 2a patient expansion stage to confirm the recommended phase 2 dose, as presented at March BIO Europe slide 11. What this likely means is that they are done with the combo trial dose escalation stage. Good news. Maybe we'll get more details at BIO International in a few weeks. Also, on slide 15 they are planning to adapt current ZEN-3694 w/ enzalutamide trial to also include ZEN-3694 w/ abiraterone. But this part doesn't yet appear on the updates ClinicalTrials.gov page. So likely in H2.